ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

DeepAtrophy: Teaching a neural network to detect progressive changes in longitudinal MRI of the hippocampal region in Alzheimer's disease

Dong, Mengjin*; Xie, Long; Das, Sandhitsu R.; Wang, Jiancong; Wisse, Laura E. M.; deFlores, Robin; Wolk, David A.; Yushkevich, Paul A.
NeuroImage2021-11DOI: 10.1016/j.neuroimage.2021.118514
10被引15阅读
引用收藏
分享

摘要

Measures of change in hippocampal volume derived from longitudinal MRI are a well-studied biomarker of disease progression in Alzheimer's disease (AD) and are used in clinical trials to track therapeutic efficacy of disease modifying treatments. However, longitudinal MRI change measures based on deformable registration can be confounded by MRI artifacts, resulting in over-estimation or underestimation of hippocampal atrophy. For example, the deformation-based-morphometry method ALOHA (Das et al., 2012) finds an increase in hippocampal volume in a substantial proportion of longitudinal scan pairs from the Alzheimer's Disease Neuroimaging Initiative (ADNI) study, unexpected, given that the hippocampal gray matter is lost with age and disease progression. We propose an alternative approach to quantify disease progression in the hippocampal region: to train a deep learning network (called DeepAtrophy) to infer temporal information from longitudinal scan pairs. The underlying assumption is that by learning to derive time-related information from scan pairs, the network implicitly learns to detect progressive changes that are related to aging and disease progression. Our network is trained using two categorical loss functions: one that measures the network's ability to correctly order two scans from the same subject, input in arbitrary order; and another that measures the ability to correctly infer the ratio of inter-scan intervals between two pairs of same-subject input scans. When applied to longitudinal MRI scan pairs from subjects unseen during training, DeepAtrophy achieves greater accuracy in scan temporal ordering and interscan interval inference tasks than ALOHA (88.5% vs. 75.5% and 81.1% vs. 75.0%, respectively). A scalar measure of time-related change in a subject level derived from DeepAtrophy is then examined as a biomarker of disease progression in the context of AD clinical trials. We find that this measure performs on par with ALOHA in discriminating groups of individuals at different stages of the AD continuum. Overall, our results suggest that using deep learning to infer temporal information from longitudinal MRI of the hippocampal region has good potential as a biomarker of disease progression, and hints that combining this approach with conventional deformation-based morphometry algorithms may lead to improved biomarkers in the future.

学科与关键词

关键词
Longitudinal analysisT1-weighted MRIAlzheimer's diseaseHippocampus areaInterscan intervalDisease progression
相关
加载中…
  • Hippocampal representations for deep learning on Alzheimer's disease
    Sarasua, Ignacio*; Polsterl, Sebastian; Wachinger, ChristianScientific Reports, 2022, 12(1): 8619.被引 6
  • Deep recurrent model for individualized prediction of Alzheimer's disease progression
    Jung, Wonsik; Jun, Eunji; Suk, Heung-Il*NeuroImage, 2021, 237: 118143.被引 40
  • Prediction of Alzheimer's progression based on multimodal Deep-Learning-based fusion and visual Explainability of time-series data
    Rahim, Nasir; El-Sappagh, Shaker*; Ali, Sajid; Muhammad, Khan*; Del Ser, Javier; Abuhmed, Tamer*Information Fusion, 2023, 92: 363-388.被引 35
查看全部 →

发表信息

论文状态
公开发表
期刊
NeuroImage
发表日期
2021-11
卷期
第 243 卷
页码
118514
DOI
10.1016/j.neuroimage.2021.118514
语言
ENGLISH
期刊收录
NSL
期刊等级
1区
成果收录
SCIE
资助标注
National Institute of Health (NIH) [R01-AG056014, R01-AG040271, P30-AG010124, R01-EB017255, R01-AG055005]; Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]; DOD ADNI (Department of De-fense) [W81XWH-12-2-0012]; Na-tional Institute on Aging; National Institute of Biomedical Imag-ing and Bioengineering; AbbVie; Alzheimer's Association; Alzheimer's Drug Discov-ery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceu-ticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Fujirebio; GE Health-care; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Devel-opment, LLC; Johnson & Johnson Pharmaceutical Research & Develop-ment LLC.; Lumosity; Lundbeck; Merck Co., Inc.; Meso Scale Diagnos-tics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Phar-maceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; Transition Therapeutics; Canadian Institutes of Health Research; National Institute on Aging [R01AG056014, R01AG055005] Funding Source: NIH RePORTER

作者

  • D

    Dong, Mengjin (通讯) (第一作者)

  • X

    Xie, Long

查看全部 8 位作者收起作者
  • D

    Das, Sandhitsu R.

  • W

    Wang, Jiancong

  • W

    Wisse, Laura E. M.

  • d

    deFlores, Robin

  • W

    Wolk, David A.

  • Y

    Yushkevich, Paul A.

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417